HKI 46F08, a novel potent histone deacetylase inhibitor, exhibits antitumoral activity against embryonic childhood cancer cells

Anti-Cancer Drugs

Volumn 19, Issue 9, 2008, Pages 849-857

  Wegener, Dennis ^a   Deubzer, Hedwig E ^a,b   Oehme, Ina ^a   Milde, Till ^a   Hildmann, Christian ^c,d   Schwienhorst, Andreas ^c   Witt, Olaf ^a,b  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c Institute for Microbiology and Genetics   (Germany)

^d ILMENAU UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

Histone deacetylase inhibitor; HKI 46F08; Medulloblastoma; Neuroblastoma

Indexed keywords

DIMETHYL SULFOXIDE; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; HKI 46F08; KETONE DERIVATIVE; MESSENGER RNA; TRIFLUOROMETHYL KETONE; UNCLASSIFIED DRUG; VALPROIC ACID;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CELL DIFFERENTIATION; CELL GROWTH; CELL PROLIFERATION; CELL VIABILITY; CHILDHOOD CANCER; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENCY; DRUG STRUCTURE; EMBRYO; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME INHIBITION; GENE EXPRESSION; GROWTH INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; MEDULLOBLASTOMA; NEUROBLASTOMA; NEUROBLASTOMA CELL; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BENZIMIDAZOLES; CELL LINE, TUMOR; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; DRUG SCREENING ASSAYS, ANTITUMOR; ENZYME INHIBITORS; HISTONE DEACETYLASES; HUMANS; MEDULLOBLASTOMA; NEUROBLASTOMA; RATS;

EID: 52649127455     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/CAD.0b013e32830efbeb     Document Type: Article

References (29)

1. De Preter K, Vandesompele J, Heimann P, Yigit N, Beckman S, Schramm A, et al. Human fetal neuroblast and neuroblastoma transcnptome analysis confirms neuroblast origin and highlights neuroblastoma candidate genes. Genome Biol 2006; 7:R84.
2. Brodeur GM. Neuroblastoma: biological insights into a clinical enigma. Wat Rev Cancer 2003; 3:203-216.
3. Berthold F, Hero B, Kremens B, Handgretinger R, Henze G, Schilling FH, et al. Long-term results and risk profiles of patients in five consecutive trials (1979-1997) with stage 4 neuroblastoma over 1 year of age. Cancer Lett 2003; 197:11-17.
4. Deubzer HE, Ehemann V, Kulozik AE, Westermann F, Savelyeva L, Kopp-Schneider A, et al. Anti-neuroblastoma activity of Helminthosporium carbonum (HC)-toxin is superior to that of other differentiating compounds in vitro. Cancer Lett 2008; 264:21-28.
5. Deubzer HE, Ehemann V, Westermann F, Heinrich R, Mechtersheimer G, Kulozik AE, et al. Histone deacetylase inhibitor Helminthosporium carbonum (HC)-toxin suppresses the malignant phenotype of neuroblastoma cells. Int J Cancer 2008; 122:1891-1900.
6. Minucci S, Pelicci PG. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nar Rev Cancer 2006; 6: 38-51.
7. Yoo CB, Jones PA. Epigenetic therapy of cancer: past, present and future. Nar Rev Drug Discov 2006; 5:37-50.
8. Richon VM, Sandhoff TW, Rifkind RA, Marks PA. Histone deacetylase inhibitor selectively induces p21 WAF1 expression and gene-associated histone acetylation. Proc Natl Acad Sci U S A 2000; 97:10014-10019.
9. Marks PA. Discovery and development of SAHA as an anticancer agent. Oncogene 2007; 26:1351-1356.
10. Wegener D, Hildmann C, Riester D, Schober A, Meyer-Almes FJ, Deubzer HE, et al. Identification of novel small-molecule histone deacetylase inhibitors by medium-throughput screening using a fluorigenic assay. Biochem J 2008; 413:143-150.
11. Zhang J, Spring H, Schwab M. Neuroblastoma tumor cell-binding peptides identified through random peptide phage display. Cancer Lett 2001; 171:153-164.
12. He XM, Wikstrand CJ, Friedman HS, Bigner SH, Pleasure S, Trojanowski JQ, et al. Differentiation characteristics of newly established medulloblastoma cell lines (D384 Med, D425 Med, and D458 Med) and their transplantable xenografts. Lab Invest 1991; 64:833-843.
13. Hare CB, Elion GB, Houghton PJ, Houghton JA, Keir S, Marcelli SL, et al. Therapeutic efficacy of the topoisomerase I inhibitor 7-ethyl-10-|4-(1-piperidino)-1-piperidino]-carbonyloxy-camptothecin against pediatric and adult central nervous system tumor xenografts. Cancer Chemother Pharmacol 1997; 39:187-191.
14. Wegener D, Hildmann C, Riester D, Schwienhorsl A. Improved fluorogenic histone deacetylase assay for high-throughput-screening applications. Anal Biochem 2003; 321:202-208.
15. Witt O, Monkemeyer S, Ronndahl G, Erdlenbruch B, Reinhardt D, Kanbach K, et al. Induction of fetal hemoglobin expression by the histone deacetylase inhibitor apicidin. Blood 2003; 101:2001-2007.
16. Cook JA, Mitchell JB. Viability measurements in mammalian cell systems. Anal Biochem 1989; 179:1-7.
17. Han JW, Ahn SH, Park SH, Wang SY, Bae GU, Seo DW, et al. Apicidin, a histone deacetylase inhibitor, inhibits proliferation of tumor cells via induction of p21 WAF1/Cip1 and gelsolin. Cancer Res 2000; 60: 6068-6074.
18. Lavelle D, Chen YH, Hankewych M, DeSimone J. Histone deacetylase inhibitors increase p21(WAF1) and induce apoptosis of human myeloma cell lines independent of decreased IL-6 receptor expression. Am J Hematol 2001; 68:170-178.
19. Rosato RR, Almenara JA, Grant S. The histone deacetylase inhibitor MS-275 promotes differentiation or apoptosis in human leukemia cells through a process regulated by generation of reactive oxygen species and induction of p21CIP1/WAF1 1. Cancer Res 2003; 63:3637-3645.
20. Sambucetti LC, Fischer DD, Zabludoff S, Kwon PO, Chamberlin H, Trogani N, et al. Histone deacetylase inhibition selectively alters the activity and expression of cell cycle proteins leading to specific chromatin acetylation and antiproliferative effects. J Biol Chem 1999; 274:34940-34947.
21. Archer SY, Meng S, Shei A, Hodin RA. p21 (WAF1) is required for butyrate-mediated growth inhibition of human colon cancer cells. Proc Natl Acad Sci U S A 1998; 95:6791-6796.
22. Deubzer H, Busche B, Ronndahl G, Eikel D, Michaelis M, Cinatl J, et al. Novel valproic acid derivatives with potent differentiation-inducing activity in myeloid leukemia cells. Leuk Res 2006; 30:1167-1175.
23. Schwab M, Varmus HE, Bishop JM. Human N-myc gene contributes to neoplastic transformation of mammalian cells in culture. Nature 1985; 316:160-162.
24. Walton JD, Kattan DR, Thomas SK, Spengler BA, Guo HF, Biedler JL, et al. Characteristics of stem cells from human neuroblastoma cell lines and in tumors. Neoplasia 2004; 6:838-845.
25. Del Prete MJ, Robles MS, Guao A, Martinez AC, Izquierdo M, Garcia-Sanz JA. Degradation of cellular mRNA is a general early apoptosis-induced event. FASEB J 2002; 16:2003-2005.
26. Jaboin J, Wild J, Hamidi H, Khanna C, Kim CJ, Robey R, et al. MS-27-275, an inhibitor of histone deacetylase, has marked in vitro and in vivo antitumor activity against pediatric solid tumors. Cancer Res 2002; 62:6108-6115.
27. Witt O, Schweigerer L, Driever PH, Wolff J, Pekrun A. Valproic acid treatment of glioblastoma multiforme in a child. Pediatr Blood Cancer 2004; 43:181.
28. Furchert SE, Lanvers-Kaminsky C, Juurgens H, Jung M, Loidl A, Fruhwald MC. Inhibitors of histone deacetylases as potential therapeutic tools for high-risk embryonal tumors of the nervous system of childhood. Int J Cancer 2007; 120:1787-1794.
29. Grant S, Easley C, Kirkpatrick P. Vorinostat. Nar Rev Drug Discov 2007; 6:21-22.